Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 HER3 targeted radiotherapy - Actinium Pharmaceuticals/AVEO Oncology

Next Previous
Drug Profile

Actinium-225 HER3 targeted radiotherapy - Actinium Pharmaceuticals/AVEO Oncology

Alternative Names: Ac-225 ErbB3 targeted radiotherapy-Actinium Pharmaceuticals/AVEO Oncology; Ac-225 HER3 targeted radiotherapy - Actinium Pharmaceuticals/AVEO Oncology; Ac-225-HER3 antibody radio conjugate; Ac-225-HER3-ARC - Actinium Pharmaceuticals; Actinium-225 ErbB3 targeted radiotherapy; Anti-HER3 antibody radioconjugate

Latest Information Update: 16 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actinium Pharmaceuticals; AVEO Oncology
  • Class Antineoplastics; Drug conjugates; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 14 Apr 2023 Pharmacodynamics data from the preclinical studies presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 11 Apr 2022 Preclinical trials in Solid tumours in USA (unspecified route)
  • 11 Apr 2022 Pharmacodynamics data from a preclinical study in Solid tumours released by Actinium Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top